Neuberger Berman Group
RCKT icon

Neuberger Berman Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Neuberger Berman Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-150,578
Closed -$3.24M – 1979
2024
Q2 		$3.24M Buy
150,578
+35,961
+31% +$826K ﹤0.01% 1000
2024
Q1 		$3.09M Buy
+114,617
New +$3.26M ﹤0.01% 1034

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group's RCKT Position: Q3 2024 in Review

Neuberger Berman Group sold out of Rocket Pharmaceuticals (RCKT) in Q3 2024, closing a stake of 150,578 shares — an estimated $3.24M sold.

Neuberger Berman Group first reported a position in RCKT in Q1 2024 and held it in 2 quarters. The position peaked at $3.24M in Q2 2024. 191 funds tracked by Wall St. Rank hold RCKT as of Q3 2024.

  • Neuberger Berman Group reported no remaining Rocket Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 150,578 Rocket Pharmaceuticals shares in Q3 2024, an estimated $3.24M.
  • Neuberger Berman Group first reported a position in Rocket Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Neuberger Berman Group's Rocket Pharmaceuticals position peaked at $3.24M in Q2 2024.
  • 191 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2024.

Based on Neuberger Berman Group's 13F filing for Q3 2024, filed 14 Nov 2024.